{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:00:42Z","timestamp":1789376442220,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd008721","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T00:00:00Z","timestamp":1416787200000}}],"reference-count":111,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008721.pub2","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T13:07:25Z","timestamp":1416834445000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Anti-vascular endothelial growth factor for proliferative diabetic retinopathy"],"prefix":"10.1002","author":[{"given":"Maria Jos\u00e9","family":"Martinez-Zapata","sequence":"first","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni M. Claret 171 Casa de Convalesc\u00e8ncia Barcelona Catalonia Spain 08041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo J","family":"Mart\u00ed-Carvajal","sequence":"additional","affiliation":[{"name":"Iberoamerican Cochrane Network; Valencia Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Sol\u00e0","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni M. Claret 171 Casa de Convalesc\u00e8ncia Barcelona Catalonia Spain 08041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 I","family":"Pijo\u00e1n","sequence":"additional","affiliation":[{"name":"Hospital Universitario Cruces; Plaza de Cruces s\/n Barakaldo Pais Vasco Spain 48903"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); BioCruces Health Research Institute; Barakaldo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A","family":"Buil-Calvo","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau; Oftalmology; Sant Antoni M\u00aa Claret 171 Barcelona Catalonian Spain 08041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep A","family":"Cordero","sequence":"additional","affiliation":[{"name":"Universitat Ramon Llull; Blanquerna School of Health Science; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R","family":"Evans","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine; Cochrane Eyes and Vision Group, ICEH; Keppel Street London UK WC1E 7HT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,24]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD008721.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.ophtha.2009.07.001","article-title":"Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial","volume":"116","author":"Ahmadieh","year":"2009","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ophtha.2011.03.036","article-title":"The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy","volume":"118","author":"Ahn","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcrs.2008.09.019","article-title":"Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study","volume":"35","author":"Cheema","year":"2009","journal-title":"Journal of Cataract and Refractive Surgery"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/bjo.2009.168997","article-title":"Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy","volume":"94","author":"Cho","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/IAE.0b013e31819a5fc2","article-title":"Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy","volume":"29","author":"Cho","year":"2009","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00417-010-1303-3","article-title":"Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy","volume":"248","author":"Lauro","year":"2010","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamaophthalmol.2013.2015","article-title":"Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy","volume":"131","author":"Diabetic Retinopathy Clinical Research Network","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0008|cit8","first-page":"709","article-title":"Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy","volume":"2","author":"El-Batarny","year":"2008","journal-title":"Clinical Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0009|cit9","first-page":"273","article-title":"Comparison of panretinal photocoagulation (PRP) with PRP plus intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy","volume":"17","author":"Ergur","year":"2009","journal-title":"Retina-Vitreus"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1111\/j.1755-3768.2011.02364.x","article-title":"Intravitreal bevacizumab versus panretinal photocoagulation for treatment-na\u00efve proliferative and severe nonproliferative diabetic retinopathy","volume":"90","author":"Ernst","year":"2012","journal-title":"Acta Ophthalmologica"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0012|cit11","first-page":"ARVO E-abstract","article-title":"Intravitreal bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non-proliferative diabetic retinopathy: a contralateral eye study","volume":"48","author":"Garcia-Aguirre","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0011|cit12","first-page":"ARVO E-abstract","article-title":"Bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non-proliferative diabetic retinopathy: a contralateral eye study","volume":"48","author":"Garcia-Aguirre","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1254-60","DOI":"10.1097\/IAE.0b013e31820a68e5","article-title":"Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage","volume":"31","author":"Farahvash","year":"2011","journal-title":"Retina"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0017|cit14","first-page":"265","article-title":"Treatment of proliferative diabetic retinopathy with intravitreal pegaptanib vs. panretinal photocoagulation","author":"Gonzalez","year":"2007","journal-title":"American Academy of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0015|cit15","first-page":"ARVO E-abstract","article-title":"Pegaptanib sodium (Macugen\u00ae) versus panretinal photocoagulation (PRP) for the regression of proliferative diabetic retinopathy","volume":"48","author":"Gonzalez","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0016|cit16","first-page":"279","article-title":"Selective VEGF Inhibition: effectiveness in modifying the progression of proliferative diabetic retinopathy","author":"Gonzalez","year":"2006","journal-title":"American Academy of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub2-BIB0014|cit17","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/bjo.2008.155663","article-title":"Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy","volume":"93","author":"Gonz\u00e1lez","year":"2009","journal-title":"British Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/112067210801800215","article-title":"Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial","volume":"18","author":"Mirshahi","year":"2008","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0020|cit19","first-page":"199","article-title":"Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy","author":"Modarres","year":"2007","journal-title":"American Academy of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0019|cit20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/112067210901900526","article-title":"Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy","volume":"19","author":"Modarres","year":"2009","journal-title":"European Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000348605","article-title":"Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial","volume":"230","author":"Preti","year":"2013","journal-title":"Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/bjophthalmol-2012-302675","article-title":"Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial","volume":"97","author":"Preti","year":"2014","journal-title":"British Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1590\/S0004-27492013000100006","article-title":"Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy","volume":"76","author":"Lucena","year":"2013","journal-title":"Arquivos Brasileiros de Oftalmologia"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10633-012-9322-5","article-title":"Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy","volume":"124","author":"Messias","year":"2012","journal-title":"Documenta Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Ramos Filho","year":"2011","journal-title":"Acta Ophthalmologica"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00417-008-0774-y","article-title":"Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)","volume":"246","author":"Rizzo","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/archophthalmol.2012.1611","article-title":"Angiofibrotic response to vascular endothelial growth factor Inhibition in diabetic retinal detachment","volume":"130","author":"Sohn","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.12669\/pjms.292.3044","article-title":"Intravitreal Avastin as an adjunct in patients with proliferative retinopathy undergoing pars plana vitrectomy","volume":"29","author":"Zaman","year":"2013","journal-title":"Pakistan Journal of Medical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ophtha.2008.12.024","article-title":"Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy","volume":"116","author":"Arimura","year":"2009","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0030|cit30","first-page":"52","article-title":"Intravitreal bevacizumab and panretinal photocoagulation as combined treatment in proliferative diabetic retinopathy","volume":"18","author":"Fulda","year":"2010","journal-title":"Retina-Vitreus"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0031|cit31","first-page":"ARVO E-abstract","article-title":"Injection of intravitreal Avastin before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy","volume":"48","author":"Genovesi-Ebert","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0032|cit32","first-page":"192","article-title":"Pegaptanib in diabetic retinopathy: improvements in diabetic macular edema, retinal neovascularization, and diabetic retinopathy severity","author":"Gonzalez","year":"2006","journal-title":"American Academy of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/IAE.0b013e3181c70168","article-title":"Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy","volume":"30","author":"Hattori","year":"2010","journal-title":"Retina"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1097\/IAE.0b013e3181b094b7","article-title":"Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage","volume":"29","author":"Huang","year":"2009","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1755-3768.2008.01353.x","article-title":"Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy","volume":"87","author":"Jiang","year":"2009","journal-title":"Acta Ophthalmologica"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","article-title":"Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)","volume":"26","author":"Jorge","year":"2006","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/IAE.0b013e31819c6302","article-title":"Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study","volume":"29","author":"Lanzagorta-Aresti","year":"2009","journal-title":"Retina"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"Article ID 2676","DOI":"10.5402\/2012\/267643","article-title":"Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy","volume":"2012","author":"L\u00f3pez-L\u00f3pez","year":"2012","journal-title":"ISRN Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1600-0420.2007.01042.x","article-title":"Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy","volume":"86","author":"Minnella","year":"2008","journal-title":"Acta Opthalmologica"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/IAE.0b013e31815e9385","article-title":"Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema","volume":"28","author":"Scott","year":"2008","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3341\/kjo.2009.23.4.266","article-title":"Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy","volume":"23","author":"Shin","year":"2009","journal-title":"Korean Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0044|cit44","first-page":"ARVO E-abstract","article-title":"Varying doses of intravitreal bevacizumab (Avastin) for the treatment of proliferative diabetic retinopathy","volume":"48","author":"Stergiou","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-0420.2007.01056.x","article-title":"Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)","volume":"86","author":"Tonello","year":"2008","journal-title":"Acta Ophthalmologica"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/IAE.0b013e3181a3b7ef","article-title":"Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy","volume":"29","author":"Yeh","year":"2009","journal-title":"Retina"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub2-BIB0047|cit47","first-page":"475","article-title":"Avastin combined with vitreous cavity injection of triamcinolone acetonide in treatment of diabetic retinopathy with macular edema","volume":"10","author":"Zhou","year":"2010","journal-title":"International Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0048|cit48","unstructured":"EUCTR2013-003272-12-GB Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003272-12\/GB"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0049|cit49","unstructured":"NCT01854593 Prospective randomized controlled study of intravitreal injection of 0.16 mg bevacizumab one day before surgery for proliferative diabetic retinopathy clinicaltrials.gov\/show\/NCT01854593"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0050|cit50","unstructured":"NCT01941329 Prospective, randomized, multicentre, open-label, phase II\/III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy (PROTEUS) clinicaltrials.gov\/show\/NCT01941329"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0051|cit51","unstructured":"NCT01976923 Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group clinicaltrials.gov\/show\/NCT01976923"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0052|cit52","unstructured":"NCT01988246 Prevention of macular edema In patients with diabetic retinopathy undergoing cataract surgery clinicaltrials.gov\/show\/NCT01988246"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0053|cit53","first-page":"84","article-title":"Retinopathy in diabetes","volume":"27 Suppl 1","author":"Fong","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals","volume":"113","author":"Adamis","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","article-title":"Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up","volume":"114","author":"Arevalo","year":"2007","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0002-9440(10)61775-0","article-title":"Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide","volume":"159","author":"Bussolati","year":"2001","journal-title":"American Journal of Pathology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2796.2003.01297.x","article-title":"Manipulating angiogenesis in medicine","volume":"255","author":"Carmeliet","year":"2004","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.iae.0000225351.87205.69","article-title":"Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy","volume":"26","author":"Chen","year":"2006","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archopht.1996.01100140281004","article-title":"Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22","volume":"114","author":"Chew","year":"1996","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2006.04.033","article-title":"A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema","volume":"113","author":"Chun","year":"2006","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub2-BIB0064|cit64","first-page":"233","article-title":"Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18","volume":"39","author":"Davis","year":"1998","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0161-6420(78)35693-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings","volume":"85","author":"Anonymous","year":"1978","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000395330","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report no. 5","volume":"2","author":"Anonymous","year":"1981","journal-title":"Developments in Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub2-BIB0068|cit68","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group","volume":"88","author":"Anonymous","year":"1981","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.1985.01050110038020","article-title":"Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group","volume":"103","author":"Anonymous","year":"1985","journal-title":"Archives of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD008721.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group","volume":"103","author":"Anonymous","year":"1985","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0071|cit71","first-page":"786","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98 Suppl","author":"Anonymous","year":"1991","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0072|cit72","first-page":"823","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98 Suppl","author":"Anonymous","year":"1991","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0073|cit73","first-page":"766","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98 Suppl","author":"Anonymous","year":"1991","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"American Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s001250051539","article-title":"Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes","volume":"43","author":"Gilbert","year":"2000","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub2-BIB0076|cit76","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0077|cit77","unstructured":"McMaster University GRADEpro 2014"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","article-title":"Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema","volume":"26","author":"Haritoglou","year":"2006","journal-title":"Retina"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.0742-3071.2001.00603.x","article-title":"What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?","volume":"19","author":"Hayward","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0080|cit80","unstructured":"Higgins JPT Green S Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1984.01040030398010","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years","volume":"102","author":"Klein","year":"1984","journal-title":"Archives of Ophthalmology"},{"issue":"19","key":"10.1002\/14651858.CD008721.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.1988.03410190112033","article-title":"Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy","volume":"260","author":"Klein","year":"1988","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1001\/archinte.1989.00390110033008","article-title":"Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?","volume":"149","author":"Klein","year":"1989","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/diacare.13.1.34","article-title":"Effect of pregnancy on progression of diabetic retinopathy","volume":"13","author":"Klein","year":"1990","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bjo.86.4.365","article-title":"Blood pressure control and diabetic retinopathy","volume":"86","author":"Klein","year":"2002","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD008721.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0161-6420(02)01074-6","article-title":"The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study","volume":"109","author":"Klein","year":"2002","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1464-5491.2002.00839.x","article-title":"Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes","volume":"19","author":"Kullberg","year":"2002","journal-title":"Diabetes Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0161-6420(02)00975-2","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema","volume":"109","author":"Martidis","year":"2002","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","article-title":"Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy","volume":"142","author":"Mason","year":"2006","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1464-5491.1995.tb00528.x","article-title":"The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study","volume":"12","author":"Mathiesen","year":"1995","journal-title":"Diabetic Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008721.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0161-6420(94)31217-6","article-title":"Ten-years incidence of visual loss in a diabetic population","volume":"101","author":"Moss","year":"1994","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0161-6420(96)30486-7","article-title":"Cigarette smoking and ten-year progression in diabetic retinopathy","volume":"103","author":"Moss","year":"1996","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1165\/ajrcmb.16.4.9115750","article-title":"Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids","volume":"16","author":"Nauck","year":"1997","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"11","key":"10.1002\/14651858.CD008721.pub2-BIB0095|cit95","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0096|cit96","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"10","key":"10.1002\/14651858.CD008721.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema","volume":"114","author":"Scott","year":"2007","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.CIR.0000080735.93327.00","article-title":"Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy","volume":"108","author":"Sennlaub","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD008721.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0420.2007.01067.x","article-title":"Complications in patients after intravitreal injection of bevacizumab","volume":"86","author":"Shima","year":"2008","journal-title":"Acta Ophthalmologica"},{"issue":"5","key":"10.1002\/14651858.CD008721.pub2-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008214.pub2","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","author":"Smith","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008721.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1002\/14651858.CD008721.pub2-BIB0102|cit102","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9131","key":"10.1002\/14651858.CD008721.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"Anonymous","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"10.1002\/14651858.CD008721.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","author":"Anonymous","year":"1998","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD008721.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/diacare.25.8.1320","article-title":"Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study","volume":"25","author":"Leiden","year":"2002","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD008721.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archopht.121.2.245","article-title":"Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study","volume":"121","author":"Leiden","year":"2003","journal-title":"Archives of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD008721.pub2-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub3","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema","author":"Virgili","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD008721.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2013.02.008","article-title":"Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials","volume":"156","author":"Zhang","year":"2013","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD008721.pub2-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008721","article-title":"Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Protocol)","author":"Martinez-Zapata","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008721.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008721.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:22:54Z","timestamp":1628547774000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008721.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,11,24]]},"references-count":111,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008721.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD008721.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,24]]}}}